LRRK2 and Parkinson disease: Furthermore, by inhibiting the kinase activity of LRRK2 with Mli-2 [48, 49], the hyperactivation of monocytes was significantly relieved, indicating the crucial role of LRRK2 in the PD RBC-EVs-driven immune dysregulation process.